Samsung BioLogics announced that that company has entered into a long term strategic manufacturing agreement with F. Hoffmann-La Roche. Samsung will manufacture Roche’s proprietary commercial biologic medicines at its two manufacturing facilities in Incheon, South Korea, one of which is currently under construction. Terms of the agreement will not be disclosed, including financial terms and products to be manufactured.
“We are pleased to announce this strategic manufacturing relationship with Roche and look forward to delivering best-in-class manufacturing services with the highest global quality standards,” said Tae-Han Kim, president and CEO of Samsung BioLogics. “This collaboration with the world’s largest biotech company is an important milestone for Samsung as it validates our long term strategy of becoming a leader in biopharmaceutical manufacturing.”
Samsung BioLogics is a full-service provider of quality-driven contract process development and cGMP manufacturing to the global biopharmaceutical industry.
Date: October 22, 2013
Source: Samsung Biologics
Filed Under: Drug Discovery